|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
52,373,000 |
Market
Cap: |
2.53(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$30.85 - $52.9 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 474 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
144,016 |
298,272 |
308,234 |
348,833 |
Total Sell Value |
$6,682,454 |
$12,749,220 |
$13,114,420 |
$14,216,679 |
Total People Sold |
6 |
7 |
7 |
7 |
Total Sell Transactions |
12 |
29 |
34 |
37 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Halpin Michael |
Chief Operating Officer |
|
2023-11-30 |
4 |
AS |
$35.41 |
$617,798 |
D/D |
(17,447) |
827 |
|
37% |
|
Halpin Michael |
Chief Operating Officer |
|
2023-11-30 |
4 |
OE |
$7.20 |
$125,618 |
D/D |
17,447 |
18,274 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-11-20 |
4 |
AS |
$36.40 |
$182,000 |
D/D |
(5,000) |
53,007 |
|
40% |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-11-20 |
4 |
OE |
$10.95 |
$54,750 |
D/D |
5,000 |
58,007 |
|
- |
|
Zerbe Robert L Md |
|
|
2023-11-15 |
4 |
AS |
$38.00 |
$11,406 |
D/D |
(300) |
33,095 |
|
45% |
|
Flynn Sean C. |
SVP, General Counsel |
|
2023-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,042 |
6,005 |
|
- |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2023-11-15 |
4 |
S |
$37.70 |
$24,954 |
D/D |
(662) |
1,305 |
|
-45% |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2023-10-02 |
4 |
D |
$33.19 |
$9,160 |
D/D |
(276) |
1,858 |
|
- |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2023-10-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
938 |
2,134 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-08-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
16,359 |
16,359 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-08-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
16,359 |
684 |
|
- |
|
Zerbe Robert L Md |
|
|
2023-07-14 |
4 |
AS |
$38.84 |
$38,840 |
D/D |
(1,000) |
33,395 |
|
-6% |
|
Zerbe Robert L Md |
|
|
2023-06-22 |
4 |
AS |
$36.00 |
$108,000 |
D/D |
(3,000) |
34,395 |
|
-4% |
|
Wright Lisa |
|
|
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
433 |
5,817 |
|
- |
|
Gilman Steven C |
|
|
2023-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
7,800 |
|
- |
|
Wright Lisa |
|
|
2023-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
5,384 |
|
- |
|
Mclaughlin Kevin F |
|
|
2023-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
8,700 |
|
- |
|
Rubino Alan L |
|
|
2023-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
17,594 |
|
- |
|
Hagen Heidi |
|
|
2023-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
15,450 |
|
- |
|
Zerbe Robert L Md |
|
|
2023-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
37,395 |
|
- |
|
Wotton Paul K |
|
|
2023-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,600 |
31,802 |
|
- |
|
Rubino Alan L |
|
|
2023-04-25 |
4 |
OE |
$10.60 |
$31,800 |
D/D |
3,000 |
14,994 |
|
- |
|
Zerbe Robert L Md |
Director |
|
2023-03-01 |
4 |
OE |
$10.60 |
$31,800 |
D/D |
3,000 |
34,795 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-02-19 |
4 |
D |
$29.82 |
$55,704 |
D/D |
(1,868) |
16,721 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,825 |
18,589 |
|
- |
|
401 Records found
|
|
Page 4 of 17 |
|
|